Supplementary information for Precision Multiparameter Tracking of Inflammation on Timescales of Hours to Years Using Serial Dried Blood Spots

Details of datasets:

Dataset A results have been previously described in part [39] and were obtained using a liquid chromatography tandem mass spectrometry (LC-MS/MS) platform consisting of an Agilent 1290 LC system operating at 600 μ L/min and an Agilent 6490 triple quadrupole MS. Replicate standards were prepared as punches of DBS (4 punches of 1.5 mm diameter filter paper were used per well). Datasets B and C employed an Eksigent microflow LC system operating at 10 μ L/min connected to a Sciex 6500 Q-trap MS. Dataset B (436 samples from four subjects) focused on measurements of a panel of gastrointestinal inflammation related proteins. Replicate standards were prepared by pipetting whole blood onto pre-cut 6 mm diameter disks of Whatman 903 filter paper in sample wells. Dataset C was comprised of two sequential panels applied to the same DBS digests.

Nine peptides were measured in all datasets (including Alb, Hx, and IgM) and 12 were measured in both Datasets A, C and D. As part of our continuing efforts to increase assay precision, the 27-plex used in Dataset C was measured as two sequential SISCAPA multiplex subpanels, both of which included the normalizing proteins albumin (Alb), hemopexin (Hx) and total immunoglobulin M (IgM). Datasets A and B were obtained using a single MRM per peptide (measured as a single multiplex panel), while Dataset C used the average of 1 to 3 of the best quality MRM transitions available for the respective peptides. Datasets B and C were each merged with Dataset A using a run-to-run scale factor for each protein in common between datasets in order to account for potential shifts in the absolute amounts of the SIS peptides during storage between the analytical runs. The scale factor was derived from the ratio of average values for a protein in subject samples that were analyzed in both Datasets (88 samples analyzed in both Datasets A and B, and 19 samples analyzed in both Datasets B and C, in each case using duplicate punches from the same DBS card). When samples from the same subject were shared between datasets this ratio was subject-specific; for subjects without shared samples an average of the subject-specific ratios was used.

PAR measurements in Datasets A and D were determined using MassHunter Quantitative Analysis (v. B.05.02), while in Datasets B and C the Sciex MultiQuant program (v. 3.0.2) was used.


CVs were typically somewhat higher in Datasets A and B, which were analyzed earlier in the process of assay optimization. In Dataset C the CV over all 26 peptides measured in two successive multiplex enrichments from 4 replicate dried blood standards in each of nine 96-well plates (72 measurements) was reduced from 10.2% prior to volume normalization to 4.6% after normalization (Supplementary Table 1). Similarly, the overall average CV in Dataset A was reduced from 9.4% to 7.4% by normalization. In Dataset B, normalization had little effect (6.5% vs 6.1%) because in this case the standards were prepared by drying the same measured volume of whole blood onto pre-cut filter paper disks in wells, such that there was little or no volume variation to correct. In Dataset C, key inflammation markers such as C-reactive protein (CRP), serum amyloid A (SAA) and lipopolysaccharide binding protein (LPSBP) showed normalized CVs in the standard samples of 3.3% - 3.7%.

Supplementary Table 1


| | Dataset A Standards | | Dataset B Standards | | Dataset C Standards | |
|---------|----------------------|-------------------------------|----------------------|-------------------------------|----------------------|-------------------------------|
| | CV Before | | CV Before | | CV Before | |
| Protein | Vol Normalization | CV After Vol Normalization | Vol Normalization | CV After Vol Normalization | Vol Normalization | CV After Vol Normalization |
| A1AG | 11.3% | 8.6% | | | 9.2% | 4.7% |
| Alb | 7.2% | 1.9% | 7.2% | 5.7% | 10.4% | 1.9% |
| C3 | 6.2% | 2.3% | | | 9.3% | 5.5% |
| CRP | 14.1% | 13.1% | 6.8% | 6.8% | 9.8% | 3.3% |
| FibG | 6.9% | 5.3% | | | 10.6% | 4.3% |
| Нр | 10.2% | 9.4% | 5.3% | 5.5% | 6.8% | 9.4% |
| Hx | 6.4% | 1.4% | 4.6% | 3.0% | 10.0% | 1.5% |
| lgM | 6.1% | 2.6% | 6.1% | 4.6% | 9.8% | 2.1% |
| LPSBP | 7.6% | 6.5% | 6.4% | 6.2% | 10.2% | 3.7% |
| MBL | 8.1% | 7.8% | 11.1% | 11.2% | 14.2% | 12.1% |
| MPO | 11.7% | 13.1% | 5.8% | 5.5% | 10.5% | 9.7% |
| SAA | 10.9% | 8.8% | 5.0% | 4.8% | 11.6% | 3.7% |
| Average | 8.9% | 6.7% | 6.5% | 5.9% | 10.2% | 4.5% |

Supplementary Table 2


| Subject | Total samples | Inflammation events | Samples with CRP>2-fold over baseline | Samples in events | Fraction samples with CRP>2-fold over baseline | Fraction samples in events |
|---------|---------------|------------------------|---|-------------------|--|-------------------------------|
| S-01 | 186 | 9 | 47 | 91 | 25% | 49% |
| S-04 | 250 | 9 | 78 | 109 | 31% | 44% |
| S-07 | 49 | | 6 | 0 | 12% | 0% |
| S-10 | 284 | 11 | 128 | 67 | 45% | 24% |
| S-17 | 87 | 1 | 30 | 8 | 34% | 9% |
| S-18 | 411 | 20 | 77 | 133 | 19% | 32% |
| S-20 | 45 | 2 | 14 | 8 | 31% | 18% |
| S-22 | 210 | 6 | 45 | 34 | 21% | 16% |




Supplementary Fig. 1. A) Amounts (fmol of peptide) for 9 proteins measured in 255 longitudinal DBS samples from subject S-04 before (top panel) or after (lower panel) DBS volume normalization by Alb, Hx, IgM. B) Amounts of 12 proteins mrasured in 411 serial samples from subject S-18 after normalization and division by personal baseline values.



Supplementary Fig 2. Whiskerplots of the amounts of 12 proteins in the baseline samples of each of 8 subjects. Protein amount has been normalized between proteins by dividing by the median amount in all subjects.



Supplementary Fig 3. Values for MPO normalized by personal baseline showing several infection events in which MPO temporarily increased.



Supplementary Fig 4. Values for IgM normalized by personal baseline showing two infection events (S-10 E11 and S-18 E6) in which IgM temporarily increased by more than 50% and the returned to baseline levels. A third event (S-01 E7) showed a temporary increase of about 30%.